Immune response to an indigenously developed hepatitis-B (Shanvac-B) vaccine in a tribal community of India

Vaccine. 2002 Oct 4;20(29-30):3431-5. doi: 10.1016/s0264-410x(02)00337-7.

Abstract

Hepatitis-B infection is highly endemic among the primitive tribes of Andaman and Nicobar Islands, India. A pilot project of hepatitis-B vaccination using indigenously developed (Shanvac-B) was initiated among the Nicobarese tribe in Car Nicobar Island. The 936 individuals negative for HBsAg and anti-HBs were administered three doses of the vaccine at 0, 1 and 6 months. The vaccine was found to be safe and efficacious with sero-protection rates of 49.1, 86.9 and 96.7% after first, second and third dose. Considering the high endemicity of the infection and small number of the tribal population, it is necessary to initiate hepatitis-B vaccination programme for this community. Since the vaccine was found to be cost-effective, it could be adopted for hepatitis-B vaccination in this community.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Female
  • Hepatitis B Antibodies / blood
  • Hepatitis B Vaccines / adverse effects
  • Hepatitis B Vaccines / immunology*
  • Humans
  • India
  • Infant
  • Infant, Newborn
  • Male
  • Vaccination

Substances

  • Hepatitis B Antibodies
  • Hepatitis B Vaccines